Skip to Content

United Therapeutics Corp - Stock Quote UTHR

Rating as of

Morningstar's United Therapeutics Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

No-Moat United Therapeutics Continues to Face Generic Competition; Maintaining FVE of $208

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

United Therapeutics specializes in therapies for pulmonary arterial hypertension, or high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Its marketed PAH portfolio includes Remodulin (subcutaneous or intravenous administration), Tyvaso (inhaled), Orenitram (oral), and Adcirca (oral). The company also sells Unituxin for high-risk neuroblastoma, but we do not consider oncology to be United Therapeutics' core competency. The company has long been a leader in the prostacyclin market for PAH, but we expect its competitive position to be challenged by generic entry as well as Johnson & Johnson's Uptravi, which J&J gained through its acquisition of Actelion in 2017. Uptravi (oral selexipag) has quickly gained share, propelled by strong clinical data, and we expect it to remain a key competitor against United's products, particularly pipeline candidate ralinepag.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - UTHR

United Therapeutics Corp's Company Profile

Business Description

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Contact
1040 Spring Street
Silver Spring, MD, 20910
T +1 301 608-9292
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Slow Growth
Employees 965